世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
膀胱がん治療薬の市場調査：化学療法が主要な薬物タイプであり続けるMarket Study on Bladder Cancer Treatment Drugs: Chemotherapy to Remain Leading Drug Type 膀胱がん治療薬市場-レポートスコープ Persistence Market Research社の調査レポート「世界の膀胱癌治療薬市場」は、機会や現在の市場環境を評価し、市場に影響を与える対応セクションに関する詳細な分析と最... もっと見る
サマリー膀胱がん治療薬市場-レポートスコープPersistence Market Research社の調査レポート「世界の膀胱癌治療薬市場」は、機会や現在の市場環境を評価し、市場に影響を与える対応セクションに関する詳細な分析と最新情報を提供します。この調査は、市場の促進要因、抑制要因、動向、機会を含む現在の市場力学に関する詳細な洞察を提供します。この市場調査の主な目的は、2023年から2033年の予測期間中に市場がどのように推移するかについての独占情報を提示することです。 市場の成功的な成長のための重要な指標は、市場の前年比（YoY）成長分析、複合年間成長率（CAGR）を含むこの包括的なレポートで提示され、Persistence Market Research社の調査で網羅的に説明されています。この調査研究は、読者が膀胱癌治療薬の需要と調査期間中の定量的な開発機会を知るためのサポートとなります。 この調査は、投資家、メーカー、サービスプロバイダー、流通業者、サプライヤーなどの景観の株主にとって有益であり、膀胱癌治療薬市場で繁栄するために適切なビジネス戦略を開発するのに役立ちます。このPersistence Market Researchの調査で示された洞察と情報は、膀胱癌治療薬市場の株主、業界専門家、投資家、研究者、記者だけでなく、ビジネス愛好家も活用することができます。 市場統計、ならびに膀胱癌治療薬市場のビジネスシナリオに影響を与えるマクロ経済変数だけでなくマクロ経済変数に関連する情報も、現在の研究に含まれています。市場の潜在的な発展に応じて、実質的な洞察も本レポートに記載されています。さらに、本レポートで提出されたデータにより、業界のマイナーな企業や新規参入者は、市場で牽引力を発揮するために適切な企業選択をする際に役立つことができます。 主要な市場セグメント Persistence Market Research社の膀胱癌治療薬市場に関する調査レポートは、癌の種類、癌のグレード、薬剤の種類、流通チャネル、地域という5つの重要なセグメントに分けられた情報を提供しています。本レポートでは、これらのカテゴリーに関連する重要な市場力学と成長パラメータに関する包括的なデータと情報を提供します。 癌の種類 非筋肉浸潤性膀胱がん 筋層浸潤性膀胱がん がんの悪性度 低悪性度膀胱がん 高悪性度膀胱がん 薬剤の種類 免疫療法 カルメット・ゲラン菌 アベルマブ ニボルマブ ペムブロリズマブ その他 化学療法 マイトマイシンC ドセタキセル パクリタキセル シスプラチン その他 標的治療薬 エルダフィチニブ エンフルトゥマブ・ベドチン-ejfv サシツズマブ・ゴビテカン その他 販売チャネル 病院薬局 小売薬局 スペシャリティファーマシー オンライン薬局 地域別 北アメリカ 中南米 ヨーロッパ 南アジア 東アジア オセアニア 中東・アフリカ 本調査で回答した主な質問 今後数年間、膀胱がん治療薬メーカーにとって最も収益性の高い市場であり続けるのはどの地域か？ トレンドの変化は市場にどのような影響を与えるか？ COVID-19の危機は市場成長にどのような影響を与えたか？ 市場関係者はどのようにして先進地域の低空飛行の機会を捉えることができるのか？ 市場関係者は、このランドスケープにおける自らのポジションを形成するために、どのような戦略を持っているのか？ 投資家が市場に投資する際に認識する必要があり、取り組む可能性のある抑制要因とは？ 市場に影響を与える発展的なトレンドは何ですか？ 膀胱がん治療薬市場の企業は、先進国および新興国での成長機会をどのように利用できるのか？ 調査方法 Persistence Market Research社の調査レポートでは、膀胱癌治療薬市場の成長に関する広範な調査を実施し、市場の将来の成長パラメータに関する結論を得るために、独自の調査手法を利用しています。この調査手法は、一次調査と二次調査を組み合わせたもので、アナリストが結論の正確性と信頼性を確保するのに役立ちます。 市場調査作成時にアナリストが参照した二次資料には、政府機関の統計、業界誌、白書、社内外の独自データベースなどがあります。アナリストは、一次資料として、本レポートの作成に貢献したシニアマネージャー、製品ポートフォリオマネージャー、CEO、副社長、マーケティング/プロダクトマネージャー、マーケットインテリジェンスマネージャーにインタビューを行った。 一次および二次リソースから取得した包括的な情報は、市場に参入している企業からの検証として機能し、膀胱癌治療薬市場の成長見通しに関するPersistence Market Researchの予測をより正確で信頼性の高いものにします。 目次1. Executive Summary1.1. Global Market Outlook 1.2. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting the Market 4. Key Success Factors 4.1. Product Adoption Analysis 4.2. Key Strategies, by Manufacturers 4.3. Regulatory Scenario 4.4. Porters Analysis 4.5. PESTLE Analysis 4.6. Supply Chain Analysis 4.7. Funding In Research & Development 4.8. Clinical Trials Analysis 4.9. Pipeline Analysis 4.10. Disease Epidemiology, by Region 4.11. Reimbursement Scenario 4.12. Parent Market Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Pharmaceutical Industry Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Rising Healthcare Spending 5.2.2. Increasing Prevalence of Cancer 5.2.3. Increasing Awareness and Supportive Government Initiatives 5.2.4. Increase in Funding for 5.2.5. Cancer Research 5.2.6. Increase In Product Launches 5.2.7. Strong Product Pipeline 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis - Impact Assessment 6.1.1. Impact of COVID-19 - 2021 Market Scenario 6.1.2. COVID-19 Impact Summary 7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012-2022 and Forecast, 2023-2033 7.1. Historical Market Value (US$ Mn) Analysis, 2012-2022 7.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Bladder Cancer Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis by Bladder Cancer Type, 2012-2022 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Bladder Cancer Type, 2023-2033 8.3.1. Non-Muscle-Invasive Bladder Cancer 8.3.2. Muscle-Invasive Bladder Cancer 8.4. Market Attractiveness Analysis by Bladder Cancer Type 9. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Cancer grade 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis by Cancer grade, 2012-2022 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Cancer grade, 2023-2033 9.3.1. Low-grade bladder cancer 9.3.2. High-grade bladder cancer 9.4. Market Attractiveness Analysis by Cancer grade 10. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Drug Type 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis by Drug Type, 2012-2022 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Drug Type, 2023-2033 10.3.1. Immunotherapy 10.3.1.1. Bacillus Calmette-Guerin 10.3.1.2. Avelumab 10.3.1.3. Nivolumab 10.3.1.4. Pembrolizumab 10.3.1.5. Others 10.3.2. Chemotherapy 10.3.2.1. Mitomycin C 10.3.2.2. Docetaxel 10.3.2.3. Paclitaxel 10.3.2.4. Cisplatin 10.3.2.5. Others 10.3.3. Targeted therapy 10.3.3.1. Erdafitinib 10.3.3.2. Enfortumab vedotin-ejfv 10.3.3.3. Sacituzumab govitecan 10.3.3.4. Others 10.4. Market Attractiveness Analysis by Drug Type 11. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Distribution Channel 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2022 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023-2033 11.3.1. Hospital Pharmacy 11.3.2. Retail Pharmacy 11.3.3. Specialty Pharmacy 11.3.4. Online Pharmacy 11.4. Market Attractiveness Analysis By Distribution Channel 12. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2012-2022 12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023-2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2012-2022 and Forecast 2023-2033 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis, By Market Taxonomy, 2012-2022 13.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy 2023-2033 13.3.1. By Country 13.3.1.1. U.S. 13.3.1.2. Canada 13.3.2. By Bladder Cancer Type 13.3.3. By Cancer Grade 13.3.4. By Drug Type 13.3.5. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Bladder Cancer Type 13.4.3. By Cancer Grade 13.4.4. By Drug Type 13.4.5. By Distribution Channel 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 13.7. Country-Level Analysis & Forecast 13.7.1. U.S. Market Analysis 13.7.1.1. .Introduction 13.7.1.2. Market Analysis and Forecast by Market Taxonomy 13.7.1.2.1. By Bladder Cancer Type 13.7.1.2.2. By Cancer Grade 13.7.1.2.3. By Drug Type 13.7.1.2.4. By Distribution Channel 13.7.2. Canada Market Analysis 13.7.2.1. Introduction 13.7.2.2. Market Analysis and Forecast by Market Taxonomy 13.7.2.2.1. By Bladder Cancer Type 13.7.2.2.2. By Cancer Grade 13.7.2.2.3. By Drug Type 13.7.2.2.4. By Distribution Channel 14. Latin America Market Analysis 2012-2022 and Forecast 2023-2033 14.1. Introduction 14.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022 14.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033 14.3.1. By Country 14.3.1.1. Mexico 14.3.1.2. Brazil 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Bladder Cancer Type 14.3.3. By Cancer Grade 14.3.4. By Drug Type 14.3.5. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Bladder Cancer Type 14.4.3. By Cancer Grade 14.4.4. By Drug Type 14.4.5. By Distribution Channel 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 14.7. Country-Level Analysis & Forecast 14.7.1. Mexico Market Analysis 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast by Market Taxonomy 14.7.1.2.1. By Bladder Cancer Type 14.7.1.2.2. By Cancer Grade 14.7.1.2.3. By Drug Type 14.7.1.2.4. By Distribution Channel 14.7.2. Brazil Market Analysis 14.7.2.1. Introduction 14.7.2.2. Market Analysis and Forecast by Market Taxonomy 14.7.2.2.1. By Bladder Cancer Type 14.7.2.2.2. By Cancer Grade 14.7.2.2.3. By Drug Type 14.7.2.2.4. By Distribution Channel 14.7.3. Argentina Market Analysis 14.7.3.1. Introduction 14.7.3.2. Market Analysis and Forecast by Market Taxonomy 14.7.3.2.1. By Bladder Cancer Type 14.7.3.2.2. By Cancer Grade 14.7.3.2.3. By Drug Type 14.7.3.2.4. By Distribution Channel 15. Europe Market Analysis 2012-2022 and Forecast 2023-2033 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Analysis, By Market Taxonomy, 2012-2022 15.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. U.K. 15.3.1.5. Spain 15.3.1.6. Poland 15.3.1.7. Russia 15.3.1.8. Rest of Europe 15.3.2. By Bladder Cancer Type 15.3.3. By Cancer Grade 15.3.4. By Drug Type 15.3.5. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Bladder Cancer Type 15.4.3. By Cancer Grade 15.4.4. By Drug Type 15.4.5. By Distribution Channel 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 15.7. Country-Level Analysis & Forecast 15.7.1. Germany Market Analysis 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Bladder Cancer Type 15.7.1.2.2. By Cancer Grade 15.7.1.2.3. By Drug Type 15.7.1.2.4. By Distribution Channel 15.7.2. Italy Market Analysis 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Bladder Cancer Type 15.7.2.2.2. By Cancer Grade 15.7.2.2.3. By Drug Type 15.7.2.2.4. By Distribution Channel 15.7.3. France Market Analysis 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast by Market Taxonomy 15.7.3.2.1. By Bladder Cancer Type 15.7.3.2.2. By Cancer Grade 15.7.3.2.3. By Drug Type 15.7.3.2.4. By Distribution Channel 15.7.4. U.K. Market Analysis 15.7.4.1. Introduction 15.7.4.2. Market Analysis and Forecast by Market Taxonomy 15.7.4.2.1. By Bladder Cancer Type 15.7.4.2.2. By Cancer Grade 15.7.4.2.3. By Drug Type 15.7.4.2.4. By Distribution Channel 15.7.5. Spain Market Analysis 15.7.5.1. Introduction 15.7.5.2. Market Analysis and Forecast by Market Taxonomy 15.7.5.2.1. By Bladder Cancer Type 15.7.5.2.2. By Cancer Grade 15.7.5.2.3. By Drug Type 15.7.5.2.4. By Distribution Channel 15.7.6. Poland Market Analysis 15.7.6.1. Introduction 15.7.6.2. Market Analysis and Forecast by Market Taxonomy 15.7.6.2.1. By Bladder Cancer Type 15.7.6.2.2. By Cancer Grade 15.7.6.2.3. By Drug Type 15.7.6.2.4. By Distribution Channel 15.7.7. Russia Market Analysis 15.7.7.1. Introduction 15.7.7.2. Market Analysis and Forecast by Market Taxonomy 15.7.7.2.1. By Bladder Cancer Type 15.7.7.2.2. By Cancer Grade 15.7.7.2.3. By Drug Type 15.7.7.2.4. By Distribution Channel 16. South Asia Market Analysis 2012-2022 and Forecast 2023-2033 16.1. Introduction 16.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022 16.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Indonesia 16.3.1.3. Malaysia 16.3.1.4. Thailand 16.3.1.5. Rest of South Asia 16.3.2. By Bladder Cancer Type 16.3.3. By Cancer Grade 16.3.4. By Drug Type 16.3.5. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Bladder Cancer Type 16.4.3. By Cancer Grade 16.4.4. By Drug Type 16.4.5. By Distribution Channel 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 16.7. Country-Level Analysis & Forecast 16.7.1. India Market Analysis 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Bladder Cancer Type 16.7.1.2.2. By Cancer Grade 16.7.1.2.3. By Drug Type 16.7.1.2.4. By Distribution Channel 16.7.2. Indonesia Market Analysis 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Bladder Cancer Type 16.7.2.2.2. By Cancer Grade 16.7.2.2.3. By Drug Type 16.7.2.2.4. By Distribution Channel 16.7.3. Malaysia Market Analysis 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Bladder Cancer Type 16.7.3.2.2. By Cancer Grade 16.7.3.2.3. By Drug Type 16.7.3.2.4. By Distribution Channel 16.7.4. Thailand Market Analysis 16.7.4.1. Introduction 16.7.4.2. Market Analysis and Forecast by Market Taxonomy 16.7.4.2.1. By Bladder Cancer Type 16.7.4.2.2. By Cancer Grade 16.7.4.2.3. By Drug Type 16.7.4.2.4. By Distribution Channel 17. East Asia Market Analysis 2012-2022 and Forecast 2023-2033 17.1. Introduction 17.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022 17.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.2. By Bladder Cancer Type 17.3.3. By Cancer Grade 17.3.4. By Drug Type 17.3.5. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Bladder Cancer Type 17.4.3. By Cancer Grade 17.4.4. By Drug Type 17.4.5. By Distribution Channel 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 17.7. Country-Level Analysis & Forecast 17.7.1. China Market Analysis 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Bladder Cancer Type 17.7.1.2.2. By Cancer Grade 17.7.1.2.3. By Drug Type 17.7.1.2.4. By Distribution Channel 17.7.2. Japan Market Analysis 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Bladder Cancer Type 17.7.2.2.2. By Cancer Grade 17.7.2.2.3. By Drug Type 17.7.2.2.4. By Distribution Channel 17.7.3. South Korea Drugs Market Analysis 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast by Market Taxonomy 17.7.3.2.1. By Bladder Cancer Type 17.7.3.2.2. By Cancer Grade 17.7.3.2.3. By Drug Type 17.7.3.2.4. By Distribution Channel 18. Oceania Market 2012-2022 and Forecast 2022-2033 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012-2022 18.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Bladder Cancer Type 18.3.3. By Cancer Grade 18.3.4. By Drug Type 18.3.5. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Bladder Cancer Type 18.4.3. By Cancer Grade 18.4.4. By Drug Type 18.4.5. By Distribution Channel 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 18.7. Country-Level Analysis & Forecast 18.7.1. Australia Market Analysis 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Bladder Cancer Type 18.7.1.2.2. By Cancer Grade 18.7.1.2.3. By Drug Type 18.7.1.2.4. By Distribution Channel 18.7.2. New Zealand Market Analysis 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Bladder Cancer Type 18.7.2.2.2. By Cancer Grade 18.7.2.2.3. By Drug Type 18.7.2.2.4. By Distribution Channel 19. Middle East and Africa (MEA) Market Analysis 2012-2022 and Forecast 2023-2033 19.1. Introduction 19.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022 19.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. South Africa 19.3.1.3. North Africa 19.3.1.4. Türkiye 19.3.1.5. Rest of Middle East and Africa 19.3.2. By Bladder Cancer Type 19.3.3. By Cancer Grade 19.3.4. By Drug Type 19.3.5. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Bladder Cancer Type 19.4.3. By Cancer Grade 19.4.4. By Drug Type 19.4.5. By Distribution Channel 19.5. Key Market Participants - Intensity Mapping 19.6. Drivers and Restraints - Impact Analysis 19.7. Country-Level Analysis & Forecast 19.7.1. GCC Countries Market Analysis 19.7.1.1. Introduction 19.7.1.2. Market Analysis and Forecast by Market Taxonomy 19.7.1.2.1. By Bladder Cancer Type 19.7.1.2.2. By Cancer Grade 19.7.1.2.3. By Drug Type 19.7.1.2.4. By Distribution Channel 19.7.2. South Africa Market Analysis 19.7.2.1. Introduction 19.7.2.2. Market Analysis and Forecast by Market Taxonomy 19.7.2.2.1. By Bladder Cancer Type 19.7.2.2.2. By Cancer Grade 19.7.2.2.3. By Drug Type 19.7.2.2.4. By Distribution Channel 19.7.3. North Africa Market Analysis 19.7.3.1. Introduction 19.7.3.2. Market Analysis and Forecast by Market Taxonomy 19.7.3.2.1. By Bladder Cancer Type 19.7.3.2.2. By Cancer Grade 19.7.3.2.3. By Drug Type 19.7.3.2.4. By Distribution Channel 19.7.4. Türkiye Market Analysis 19.7.4.1. Introduction 19.7.4.2. Market Analysis and Forecast by Market Taxonomy 19.7.4.2.1. By Bladder Cancer Type 19.7.4.2.2. By Cancer Grade 19.7.4.2.3. By Drug Type 19.7.4.2.4. By Distribution Channel 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Share Analysis of Top Players 20.3. Market Presence Analysis 20.3.1. By Regional footprint of Players 20.3.2. Product footprint by Players 20.3.3. Channel Foot Print by Players 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive [Tentative list] 21.3.1. Pfizer Inc. 21.3.1.1. Overview 21.3.1.2. Product Portfolio 21.3.1.3. Business Segment Overview 21.3.1.4. Sales Footprint 21.3.1.5. SWOT Analysis 21.3.1.6. Key Financials 21.3.1.7. Strategy Overview 21.3.2. Merck KGaA 21.3.2.1. Overview 21.3.2.2. Product Portfolio 21.3.2.3. Business Segment Overview 21.3.2.4. Sales Footprint 21.3.2.5. SWOT Analysis 21.3.2.6. Key Financials 21.3.2.7. Strategy Overview 21.3.3. Merck & Co 21.3.3.1. Overview 21.3.3.2. Product Portfolio 21.3.3.3. Business Segment Overview 21.3.3.4. Sales Footprint 21.3.3.5. SWOT Analysis 21.3.3.6. Key Financials 21.3.3.7. Strategy Overview 21.3.4. AstraZeneca PLC 21.3.4.1. Overview 21.3.4.2. Product Portfolio 21.3.4.3. Business Segment Overview 21.3.4.4. Sales Footprint 21.3.4.5. SWOT Analysis 21.3.4.6. Key Financials 21.3.4.7. Strategy Overview 21.3.5. Roche Holding AG (Genentech) 21.3.5.1. Overview 21.3.5.2. Product Portfolio 21.3.5.3. Business Segment Overview 21.3.5.4. Sales Footprint 21.3.5.5. SWOT Analysis 21.3.5.6. Key Financials 21.3.5.7. Strategy Overview 21.3.6. Astellas Pharma Inc. 21.3.6.1. Overview 21.3.6.2. Product Portfolio 21.3.6.3. Business Segment Overview 21.3.6.4. Sales Footprint 21.3.6.5. SWOT Analysis 21.3.6.6. Key Financials 21.3.6.7. Strategy Overview 21.3.7. J&J (Janssen Biotech) 21.3.7.1. Overview 21.3.7.2. Product Portfolio 21.3.7.3. Business Segment Overview 21.3.7.4. Sales Footprint 21.3.7.5. SWOT Analysis 21.3.7.6. Key Financials 21.3.7.7. Strategy Overview 21.3.8. Cipla Inc. 21.3.8.1. Overview 21.3.8.2. Product Portfolio 21.3.8.3. Business Segment Overview 21.3.8.4. Sales Footprint 21.3.8.5. SWOT Analysis 21.3.8.6. Key Financials 21.3.8.7. Strategy Overview 21.3.9. Amneal Pharma 21.3.9.1. Overview 21.3.9.2. Product Portfolio 21.3.9.3. Business Segment Overview 21.3.9.4. Sales Footprint 21.3.9.5. SWOT Analysis 21.3.9.6. Key Financials 21.3.9.7. Strategy Overview 21.3.10. Bristol Myers Squibb Co. 21.3.10.1. Overview 21.3.10.2. Product Portfolio 21.3.10.3. Business Segment Overview 21.3.10.4. Sales Footprint 21.3.10.5. SWOT Analysis 21.3.10.6. Key Financials 21.3.10.7. Strategy Overview 21.3.11. Dr. Reddy’s Laboratories, Inc. 21.3.11.1. Overview 21.3.11.2. Product Portfolio 21.3.11.3. Business Segment Overview 21.3.11.4. Sales Footprint 21.3.11.5. SWOT Analysis 21.3.11.6. Key Financials 21.3.11.7. Strategy Overview 21.3.12. Gilead Sciences Inc. 21.3.12.1. Overview 21.3.12.2. Product Portfolio 21.3.12.3. Business Segment Overview 21.3.12.4. Sales Footprint 21.3.12.5. SWOT Analysis 21.3.12.6. Key Financials 21.3.12.7. Strategy Overview 21.3.13. Endo Pharma 21.3.13.1. Overview 21.3.13.2. Product Portfolio 21.3.13.3. Business Segment Overview 21.3.13.4. Sales Footprint 21.3.13.5. SWOT Analysis 21.3.13.6. Key Financials 21.3.13.7. Strategy Overview 21.3.14. UroGen Pharma, Inc. 21.3.14.1. Overview 21.3.14.2. Product Portfolio 21.3.14.3. Business Segment Overview 21.3.14.4. Sales Footprint 21.3.14.5. SWOT Analysis 21.3.14.6. Key Financials 21.3.14.7. Strategy Overview 21.3.15. Teva Pharmaceuticals (Actavis) 21.3.15.1. Overview 21.3.15.2. Product Portfolio 21.3.15.3. Business Segment Overview 21.3.15.4. Sales Footprint 21.3.15.5. SWOT Analysis 21.3.15.6. Key Financials 21.3.15.7. Strategy Overview 21.3.16. Hikma Pharmaceuticals 21.3.16.1. Overview 21.3.16.2. Product Portfolio 21.3.16.3. Business Segment Overview 21.3.16.4. Sales Footprint 21.3.16.5. SWOT Analysis 21.3.16.6. Key Financials 21.3.16.7. Strategy Overview 21.3.17. Incyte 21.3.17.1. Overview 21.3.17.2. Product Portfolio 21.3.17.3. Business Segment Overview 21.3.17.4. Sales Footprint 21.3.17.5. SWOT Analysis 21.3.17.6. Key Financials 21.3.17.7. Strategy Overview 22. Assumptions and Acronyms Used 23. Research Methodology 図表リストTable 01: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer TypeTable 02: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type Table 03: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade Table 04: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade Table 05: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type Table 06: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type Table 07: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel Table 08: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel Table 09: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Region Table 10: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Region Table 11: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country Table 12: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country Table 13: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type Table 14: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type Table 15: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade Table 16: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade Table 17: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type Table 18: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type Table 19: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel Table 20: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel Table 21: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country Table 22: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country Table 23: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type Table 24: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type Table 25: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade Table 26: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade Table 27: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type Table 28: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type Table 29: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel Table 30: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel Table 31: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country Table 32: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country Table 33: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type Table 34: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type Table 35: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade Table 36: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade Table 37: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type Table 38: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type Table 39: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel Table 40: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel Table 41: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country Table 42: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country Table 43: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type Table 44: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type Table 45: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade Table 46: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade Table 47: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type Table 48: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type Table 49: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel Table 50: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel Table 51: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country Table 52: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country Table 53: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type Table 54: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type Table 55: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade Table 56: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade Table 57: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type Table 58: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type Table 59: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel Table 60: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel Table 61: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country Table 62: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country Table 63: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type Table 64: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type Table 65: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade Table 66: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade Table 67: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type Table 68: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type Table 69: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel Table 70: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel Table 71: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country Table 72: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country Table 73: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type Table 74: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type Table 75: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade Table 76: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade Table 77: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type Table 78: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type Table 79: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel Table 80: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel
SummaryBladder Cancer Treatment Drugs Market – Report Scope Table of Contents1. Executive Summary1.1. Global Market Outlook 1.2. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting the Market 4. Key Success Factors 4.1. Product Adoption Analysis 4.2. Key Strategies, by Manufacturers 4.3. Regulatory Scenario 4.4. Porters Analysis 4.5. PESTLE Analysis 4.6. Supply Chain Analysis 4.7. Funding In Research & Development 4.8. Clinical Trials Analysis 4.9. Pipeline Analysis 4.10. Disease Epidemiology, by Region 4.11. Reimbursement Scenario 4.12. Parent Market Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Pharmaceutical Industry Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Rising Healthcare Spending 5.2.2. Increasing Prevalence of Cancer 5.2.3. Increasing Awareness and Supportive Government Initiatives 5.2.4. Increase in Funding for 5.2.5. Cancer Research 5.2.6. Increase In Product Launches 5.2.7. Strong Product Pipeline 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis - Impact Assessment 6.1.1. Impact of COVID-19 - 2021 Market Scenario 6.1.2. COVID-19 Impact Summary 7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012-2022 and Forecast, 2023-2033 7.1. Historical Market Value (US$ Mn) Analysis, 2012-2022 7.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Bladder Cancer Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis by Bladder Cancer Type, 2012-2022 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Bladder Cancer Type, 2023-2033 8.3.1. Non-Muscle-Invasive Bladder Cancer 8.3.2. Muscle-Invasive Bladder Cancer 8.4. Market Attractiveness Analysis by Bladder Cancer Type 9. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Cancer grade 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis by Cancer grade, 2012-2022 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Cancer grade, 2023-2033 9.3.1. Low-grade bladder cancer 9.3.2. High-grade bladder cancer 9.4. Market Attractiveness Analysis by Cancer grade 10. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Drug Type 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis by Drug Type, 2012-2022 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Drug Type, 2023-2033 10.3.1. Immunotherapy 10.3.1.1. Bacillus Calmette-Guerin 10.3.1.2. Avelumab 10.3.1.3. Nivolumab 10.3.1.4. Pembrolizumab 10.3.1.5. Others 10.3.2. Chemotherapy 10.3.2.1. Mitomycin C 10.3.2.2. Docetaxel 10.3.2.3. Paclitaxel 10.3.2.4. Cisplatin 10.3.2.5. Others 10.3.3. Targeted therapy 10.3.3.1. Erdafitinib 10.3.3.2. Enfortumab vedotin-ejfv 10.3.3.3. Sacituzumab govitecan 10.3.3.4. Others 10.4. Market Attractiveness Analysis by Drug Type 11. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Distribution Channel 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2022 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023-2033 11.3.1. Hospital Pharmacy 11.3.2. Retail Pharmacy 11.3.3. Specialty Pharmacy 11.3.4. Online Pharmacy 11.4. Market Attractiveness Analysis By Distribution Channel 12. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2012-2022 12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023-2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2012-2022 and Forecast 2023-2033 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis, By Market Taxonomy, 2012-2022 13.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy 2023-2033 13.3.1. By Country 13.3.1.1. U.S. 13.3.1.2. Canada 13.3.2. By Bladder Cancer Type 13.3.3. By Cancer Grade 13.3.4. By Drug Type 13.3.5. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Bladder Cancer Type 13.4.3. By Cancer Grade 13.4.4. By Drug Type 13.4.5. By Distribution Channel 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 13.7. Country-Level Analysis & Forecast 13.7.1. U.S. Market Analysis 13.7.1.1. .Introduction 13.7.1.2. Market Analysis and Forecast by Market Taxonomy 13.7.1.2.1. By Bladder Cancer Type 13.7.1.2.2. By Cancer Grade 13.7.1.2.3. By Drug Type 13.7.1.2.4. By Distribution Channel 13.7.2. Canada Market Analysis 13.7.2.1. Introduction 13.7.2.2. Market Analysis and Forecast by Market Taxonomy 13.7.2.2.1. By Bladder Cancer Type 13.7.2.2.2. By Cancer Grade 13.7.2.2.3. By Drug Type 13.7.2.2.4. By Distribution Channel 14. Latin America Market Analysis 2012-2022 and Forecast 2023-2033 14.1. Introduction 14.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022 14.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033 14.3.1. By Country 14.3.1.1. Mexico 14.3.1.2. Brazil 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Bladder Cancer Type 14.3.3. By Cancer Grade 14.3.4. By Drug Type 14.3.5. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Bladder Cancer Type 14.4.3. By Cancer Grade 14.4.4. By Drug Type 14.4.5. By Distribution Channel 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 14.7. Country-Level Analysis & Forecast 14.7.1. Mexico Market Analysis 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast by Market Taxonomy 14.7.1.2.1. By Bladder Cancer Type 14.7.1.2.2. By Cancer Grade 14.7.1.2.3. By Drug Type 14.7.1.2.4. By Distribution Channel 14.7.2. Brazil Market Analysis 14.7.2.1. Introduction 14.7.2.2. Market Analysis and Forecast by Market Taxonomy 14.7.2.2.1. By Bladder Cancer Type 14.7.2.2.2. By Cancer Grade 14.7.2.2.3. By Drug Type 14.7.2.2.4. By Distribution Channel 14.7.3. Argentina Market Analysis 14.7.3.1. Introduction 14.7.3.2. Market Analysis and Forecast by Market Taxonomy 14.7.3.2.1. By Bladder Cancer Type 14.7.3.2.2. By Cancer Grade 14.7.3.2.3. By Drug Type 14.7.3.2.4. By Distribution Channel 15. Europe Market Analysis 2012-2022 and Forecast 2023-2033 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Analysis, By Market Taxonomy, 2012-2022 15.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. U.K. 15.3.1.5. Spain 15.3.1.6. Poland 15.3.1.7. Russia 15.3.1.8. Rest of Europe 15.3.2. By Bladder Cancer Type 15.3.3. By Cancer Grade 15.3.4. By Drug Type 15.3.5. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Bladder Cancer Type 15.4.3. By Cancer Grade 15.4.4. By Drug Type 15.4.5. By Distribution Channel 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 15.7. Country-Level Analysis & Forecast 15.7.1. Germany Market Analysis 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Bladder Cancer Type 15.7.1.2.2. By Cancer Grade 15.7.1.2.3. By Drug Type 15.7.1.2.4. By Distribution Channel 15.7.2. Italy Market Analysis 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Bladder Cancer Type 15.7.2.2.2. By Cancer Grade 15.7.2.2.3. By Drug Type 15.7.2.2.4. By Distribution Channel 15.7.3. France Market Analysis 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast by Market Taxonomy 15.7.3.2.1. By Bladder Cancer Type 15.7.3.2.2. By Cancer Grade 15.7.3.2.3. By Drug Type 15.7.3.2.4. By Distribution Channel 15.7.4. U.K. Market Analysis 15.7.4.1. Introduction 15.7.4.2. Market Analysis and Forecast by Market Taxonomy 15.7.4.2.1. By Bladder Cancer Type 15.7.4.2.2. By Cancer Grade 15.7.4.2.3. By Drug Type 15.7.4.2.4. By Distribution Channel 15.7.5. Spain Market Analysis 15.7.5.1. Introduction 15.7.5.2. Market Analysis and Forecast by Market Taxonomy 15.7.5.2.1. By Bladder Cancer Type 15.7.5.2.2. By Cancer Grade 15.7.5.2.3. By Drug Type 15.7.5.2.4. By Distribution Channel 15.7.6. Poland Market Analysis 15.7.6.1. Introduction 15.7.6.2. Market Analysis and Forecast by Market Taxonomy 15.7.6.2.1. By Bladder Cancer Type 15.7.6.2.2. By Cancer Grade 15.7.6.2.3. By Drug Type 15.7.6.2.4. By Distribution Channel 15.7.7. Russia Market Analysis 15.7.7.1. Introduction 15.7.7.2. Market Analysis and Forecast by Market Taxonomy 15.7.7.2.1. By Bladder Cancer Type 15.7.7.2.2. By Cancer Grade 15.7.7.2.3. By Drug Type 15.7.7.2.4. By Distribution Channel 16. South Asia Market Analysis 2012-2022 and Forecast 2023-2033 16.1. Introduction 16.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022 16.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Indonesia 16.3.1.3. Malaysia 16.3.1.4. Thailand 16.3.1.5. Rest of South Asia 16.3.2. By Bladder Cancer Type 16.3.3. By Cancer Grade 16.3.4. By Drug Type 16.3.5. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Bladder Cancer Type 16.4.3. By Cancer Grade 16.4.4. By Drug Type 16.4.5. By Distribution Channel 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 16.7. Country-Level Analysis & Forecast 16.7.1. India Market Analysis 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Bladder Cancer Type 16.7.1.2.2. By Cancer Grade 16.7.1.2.3. By Drug Type 16.7.1.2.4. By Distribution Channel 16.7.2. Indonesia Market Analysis 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Bladder Cancer Type 16.7.2.2.2. By Cancer Grade 16.7.2.2.3. By Drug Type 16.7.2.2.4. By Distribution Channel 16.7.3. Malaysia Market Analysis 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Bladder Cancer Type 16.7.3.2.2. By Cancer Grade 16.7.3.2.3. By Drug Type 16.7.3.2.4. By Distribution Channel 16.7.4. Thailand Market Analysis 16.7.4.1. Introduction 16.7.4.2. Market Analysis and Forecast by Market Taxonomy 16.7.4.2.1. By Bladder Cancer Type 16.7.4.2.2. By Cancer Grade 16.7.4.2.3. By Drug Type 16.7.4.2.4. By Distribution Channel 17. East Asia Market Analysis 2012-2022 and Forecast 2023-2033 17.1. Introduction 17.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022 17.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.2. By Bladder Cancer Type 17.3.3. By Cancer Grade 17.3.4. By Drug Type 17.3.5. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Bladder Cancer Type 17.4.3. By Cancer Grade 17.4.4. By Drug Type 17.4.5. By Distribution Channel 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 17.7. Country-Level Analysis & Forecast 17.7.1. China Market Analysis 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Bladder Cancer Type 17.7.1.2.2. By Cancer Grade 17.7.1.2.3. By Drug Type 17.7.1.2.4. By Distribution Channel 17.7.2. Japan Market Analysis 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Bladder Cancer Type 17.7.2.2.2. By Cancer Grade 17.7.2.2.3. By Drug Type 17.7.2.2.4. By Distribution Channel 17.7.3. South Korea Drugs Market Analysis 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast by Market Taxonomy 17.7.3.2.1. By Bladder Cancer Type 17.7.3.2.2. By Cancer Grade 17.7.3.2.3. By Drug Type 17.7.3.2.4. By Distribution Channel 18. Oceania Market 2012-2022 and Forecast 2022-2033 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012-2022 18.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Bladder Cancer Type 18.3.3. By Cancer Grade 18.3.4. By Drug Type 18.3.5. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Bladder Cancer Type 18.4.3. By Cancer Grade 18.4.4. By Drug Type 18.4.5. By Distribution Channel 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 18.7. Country-Level Analysis & Forecast 18.7.1. Australia Market Analysis 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Bladder Cancer Type 18.7.1.2.2. By Cancer Grade 18.7.1.2.3. By Drug Type 18.7.1.2.4. By Distribution Channel 18.7.2. New Zealand Market Analysis 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Bladder Cancer Type 18.7.2.2.2. By Cancer Grade 18.7.2.2.3. By Drug Type 18.7.2.2.4. By Distribution Channel 19. Middle East and Africa (MEA) Market Analysis 2012-2022 and Forecast 2023-2033 19.1. Introduction 19.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022 19.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. South Africa 19.3.1.3. North Africa 19.3.1.4. Türkiye 19.3.1.5. Rest of Middle East and Africa 19.3.2. By Bladder Cancer Type 19.3.3. By Cancer Grade 19.3.4. By Drug Type 19.3.5. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Bladder Cancer Type 19.4.3. By Cancer Grade 19.4.4. By Drug Type 19.4.5. By Distribution Channel 19.5. Key Market Participants - Intensity Mapping 19.6. Drivers and Restraints - Impact Analysis 19.7. Country-Level Analysis & Forecast 19.7.1. GCC Countries Market Analysis 19.7.1.1. Introduction 19.7.1.2. Market Analysis and Forecast by Market Taxonomy 19.7.1.2.1. By Bladder Cancer Type 19.7.1.2.2. By Cancer Grade 19.7.1.2.3. By Drug Type 19.7.1.2.4. By Distribution Channel 19.7.2. South Africa Market Analysis 19.7.2.1. Introduction 19.7.2.2. Market Analysis and Forecast by Market Taxonomy 19.7.2.2.1. By Bladder Cancer Type 19.7.2.2.2. By Cancer Grade 19.7.2.2.3. By Drug Type 19.7.2.2.4. By Distribution Channel 19.7.3. North Africa Market Analysis 19.7.3.1. Introduction 19.7.3.2. Market Analysis and Forecast by Market Taxonomy 19.7.3.2.1. By Bladder Cancer Type 19.7.3.2.2. By Cancer Grade 19.7.3.2.3. By Drug Type 19.7.3.2.4. By Distribution Channel 19.7.4. Türkiye Market Analysis 19.7.4.1. Introduction 19.7.4.2. Market Analysis and Forecast by Market Taxonomy 19.7.4.2.1. By Bladder Cancer Type 19.7.4.2.2. By Cancer Grade 19.7.4.2.3. By Drug Type 19.7.4.2.4. By Distribution Channel 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Share Analysis of Top Players 20.3. Market Presence Analysis 20.3.1. By Regional footprint of Players 20.3.2. Product footprint by Players 20.3.3. Channel Foot Print by Players 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive [Tentative list] 21.3.1. Pfizer Inc. 21.3.1.1. Overview 21.3.1.2. Product Portfolio 21.3.1.3. Business Segment Overview 21.3.1.4. Sales Footprint 21.3.1.5. SWOT Analysis 21.3.1.6. Key Financials 21.3.1.7. Strategy Overview 21.3.2. Merck KGaA 21.3.2.1. Overview 21.3.2.2. Product Portfolio 21.3.2.3. Business Segment Overview 21.3.2.4. Sales Footprint 21.3.2.5. SWOT Analysis 21.3.2.6. Key Financials 21.3.2.7. Strategy Overview 21.3.3. Merck & Co 21.3.3.1. Overview 21.3.3.2. Product Portfolio 21.3.3.3. Business Segment Overview 21.3.3.4. Sales Footprint 21.3.3.5. SWOT Analysis 21.3.3.6. Key Financials 21.3.3.7. Strategy Overview 21.3.4. AstraZeneca PLC 21.3.4.1. Overview 21.3.4.2. Product Portfolio 21.3.4.3. Business Segment Overview 21.3.4.4. Sales Footprint 21.3.4.5. SWOT Analysis 21.3.4.6. Key Financials 21.3.4.7. Strategy Overview 21.3.5. Roche Holding AG (Genentech) 21.3.5.1. Overview 21.3.5.2. Product Portfolio 21.3.5.3. Business Segment Overview 21.3.5.4. Sales Footprint 21.3.5.5. SWOT Analysis 21.3.5.6. Key Financials 21.3.5.7. Strategy Overview 21.3.6. Astellas Pharma Inc. 21.3.6.1. Overview 21.3.6.2. Product Portfolio 21.3.6.3. Business Segment Overview 21.3.6.4. Sales Footprint 21.3.6.5. SWOT Analysis 21.3.6.6. Key Financials 21.3.6.7. Strategy Overview 21.3.7. J&J (Janssen Biotech) 21.3.7.1. Overview 21.3.7.2. Product Portfolio 21.3.7.3. Business Segment Overview 21.3.7.4. Sales Footprint 21.3.7.5. SWOT Analysis 21.3.7.6. Key Financials 21.3.7.7. Strategy Overview 21.3.8. Cipla Inc. 21.3.8.1. Overview 21.3.8.2. Product Portfolio 21.3.8.3. Business Segment Overview 21.3.8.4. Sales Footprint 21.3.8.5. SWOT Analysis 21.3.8.6. Key Financials 21.3.8.7. Strategy Overview 21.3.9. Amneal Pharma 21.3.9.1. Overview 21.3.9.2. Product Portfolio 21.3.9.3. Business Segment Overview 21.3.9.4. Sales Footprint 21.3.9.5. SWOT Analysis 21.3.9.6. Key Financials 21.3.9.7. Strategy Overview 21.3.10. Bristol Myers Squibb Co. 21.3.10.1. Overview 21.3.10.2. Product Portfolio 21.3.10.3. Business Segment Overview 21.3.10.4. Sales Footprint 21.3.10.5. SWOT Analysis 21.3.10.6. Key Financials 21.3.10.7. Strategy Overview 21.3.11. Dr. Reddy’s Laboratories, Inc. 21.3.11.1. Overview 21.3.11.2. Product Portfolio 21.3.11.3. Business Segment Overview 21.3.11.4. Sales Footprint 21.3.11.5. SWOT Analysis 21.3.11.6. Key Financials 21.3.11.7. Strategy Overview 21.3.12. Gilead Sciences Inc. 21.3.12.1. Overview 21.3.12.2. Product Portfolio 21.3.12.3. Business Segment Overview 21.3.12.4. Sales Footprint 21.3.12.5. SWOT Analysis 21.3.12.6. Key Financials 21.3.12.7. Strategy Overview 21.3.13. Endo Pharma 21.3.13.1. Overview 21.3.13.2. Product Portfolio 21.3.13.3. Business Segment Overview 21.3.13.4. Sales Footprint 21.3.13.5. SWOT Analysis 21.3.13.6. Key Financials 21.3.13.7. Strategy Overview 21.3.14. UroGen Pharma, Inc. 21.3.14.1. Overview 21.3.14.2. Product Portfolio 21.3.14.3. Business Segment Overview 21.3.14.4. Sales Footprint 21.3.14.5. SWOT Analysis 21.3.14.6. Key Financials 21.3.14.7. Strategy Overview 21.3.15. Teva Pharmaceuticals (Actavis) 21.3.15.1. Overview 21.3.15.2. Product Portfolio 21.3.15.3. Business Segment Overview 21.3.15.4. Sales Footprint 21.3.15.5. SWOT Analysis 21.3.15.6. Key Financials 21.3.15.7. Strategy Overview 21.3.16. Hikma Pharmaceuticals 21.3.16.1. Overview 21.3.16.2. Product Portfolio 21.3.16.3. Business Segment Overview 21.3.16.4. Sales Footprint 21.3.16.5. SWOT Analysis 21.3.16.6. Key Financials 21.3.16.7. Strategy Overview 21.3.17. Incyte 21.3.17.1. Overview 21.3.17.2. Product Portfolio 21.3.17.3. Business Segment Overview 21.3.17.4. Sales Footprint 21.3.17.5. SWOT Analysis 21.3.17.6. Key Financials 21.3.17.7. Strategy Overview 22. Assumptions and Acronyms Used 23. Research Methodology List of Tables/GraphsTable 01: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer TypeTable 02: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type Table 03: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade Table 04: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade Table 05: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type Table 06: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type Table 07: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel Table 08: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel Table 09: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Region Table 10: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Region Table 11: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country Table 12: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country Table 13: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type Table 14: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type Table 15: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade Table 16: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade Table 17: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type Table 18: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type Table 19: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel Table 20: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel Table 21: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country Table 22: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country Table 23: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type Table 24: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type Table 25: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade Table 26: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade Table 27: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type Table 28: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type Table 29: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel Table 30: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel Table 31: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country Table 32: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country Table 33: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type Table 34: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type Table 35: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade Table 36: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade Table 37: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type Table 38: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type Table 39: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel Table 40: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel Table 41: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country Table 42: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country Table 43: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type Table 44: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type Table 45: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade Table 46: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade Table 47: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type Table 48: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type Table 49: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel Table 50: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel Table 51: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country Table 52: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country Table 53: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type Table 54: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type Table 55: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade Table 56: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade Table 57: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type Table 58: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type Table 59: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel Table 60: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel Table 61: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country Table 62: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country Table 63: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type Table 64: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type Table 65: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade Table 66: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade Table 67: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type Table 68: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type Table 69: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel Table 70: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel Table 71: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country Table 72: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country Table 73: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type Table 74: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type Table 75: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade Table 76: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade Table 77: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type Table 78: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type Table 79: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel Table 80: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療機器）の最新刊レポート
Persistence Market Research社の医療・製薬・メディカルデバイス分野での最新刊レポート
本レポートと同じKEY WORD（bladder cancer）の最新刊レポート
よくあるご質問Persistence Market Research社はどのような調査会社ですか?パーシスタンスマーケットリサーチ（Persistence Market Research/PMR）は独自の方法論を用いたデータ解析と市場調査をベースに広範な産業調査報告書とカスタム調査を提供しています... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/14 10:27 156.77 円 166.04 円 201.95 円 |
